Lifesci Capital Weighs in on SLNO Q4 Earnings

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Analysts at Lifesci Capital issued their Q4 2024 earnings per share estimates for Soleno Therapeutics in a research report issued to clients and investors on Tuesday, February 4th. Lifesci Capital analyst M. Belghiti expects that the company will earn ($0.37) per share for the quarter. Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share. Lifesci Capital also issued estimates for Soleno Therapeutics’ Q1 2025 earnings at ($1.67) EPS, Q2 2025 earnings at ($1.13) EPS, Q3 2025 earnings at ($1.03) EPS, Q4 2025 earnings at ($0.80) EPS, FY2025 earnings at ($3.32) EPS, Q1 2026 earnings at ($1.55) EPS, Q2 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at ($0.11) EPS, FY2026 earnings at ($1.54) EPS, FY2027 earnings at $5.58 EPS, FY2028 earnings at $9.47 EPS and FY2029 earnings at $9.99 EPS.

Other equities research analysts have also issued research reports about the stock. Robert W. Baird reaffirmed an “outperform” rating and set a $72.00 target price on shares of Soleno Therapeutics in a report on Monday, December 2nd. Stifel Nicolaus reissued a “buy” rating and set a $74.00 price objective on shares of Soleno Therapeutics in a research report on Monday, December 2nd. Oppenheimer increased their target price on Soleno Therapeutics from $65.00 to $73.00 and gave the stock an “outperform” rating in a research note on Monday, October 28th. Finally, HC Wainwright reiterated a “buy” rating and issued a $70.00 price objective on shares of Soleno Therapeutics in a research note on Monday, December 2nd. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $71.20.

Soleno Therapeutics Stock Performance

Shares of SLNO opened at $50.98 on Thursday. Soleno Therapeutics has a one year low of $36.61 and a one year high of $60.92. The stock has a 50-day moving average of $47.33 and a two-hundred day moving average of $49.82. The stock has a market cap of $2.20 billion, a P/E ratio of -15.36 and a beta of -1.46.

Soleno Therapeutics (NASDAQ:SLNO) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($1.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by ($1.22).

Insider Buying and Selling at Soleno Therapeutics

In related news, insider Kristen Yen sold 2,340 shares of the company’s stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $46.18, for a total transaction of $108,061.20. Following the completion of the transaction, the insider now directly owns 76,605 shares in the company, valued at $3,537,618.90. This represents a 2.96 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Bhatnagar Anish sold 10,937 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $45.41, for a total transaction of $496,649.17. Following the completion of the sale, the chief executive officer now owns 708,616 shares of the company’s stock, valued at approximately $32,178,252.56. The trade was a 1.52 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 17,360 shares of company stock worth $790,119. 12.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. US Bancorp DE acquired a new position in shares of Soleno Therapeutics during the 4th quarter worth approximately $34,000. Avanza Fonder AB bought a new stake in shares of Soleno Therapeutics in the fourth quarter valued at approximately $76,000. Avior Wealth Management LLC bought a new position in shares of Soleno Therapeutics in the fourth quarter worth $89,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Soleno Therapeutics in the 3rd quarter valued at approximately $155,000. Finally, Curi RMB Capital LLC bought a new stake in Soleno Therapeutics during the third quarter worth $202,000. Institutional investors and hedge funds own 97.42% of the company’s stock.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.